Acetyl-CoA acyltransferase (ACAA) was shown to have a negative correlation with the resistance of the targeted cancer drug, cetuximab, in CRC which the overexpression of ACAA would suppress proliferation and lower cetuximab tolerance in CRC cells [110]. This evidence concerns the gene ACAA1 and colorectal carcinoma.